Lamia Rhymee
A5050278796- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Lung Cancer Treatments and Mutations
- RNA modifications and cancer
- Single-cell and spatial transcriptomics
- Lung Cancer Research Studies
- Ferroptosis and cancer prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Epigenetics and DNA Methylation
- Mycobacterium research and diagnosis
- Monoclonal and Polyclonal Antibodies Research
- Immune cells in cancer
- Esophageal Cancer Research and Treatment
- Lymphoma Diagnosis and Treatment
Sidney Kimmel Comprehensive Cancer Center
2018-2023
Johns Hopkins University
2018-2023
University of Baltimore
2021
Abstract Despite the initial successes of immunotherapy, there is an urgent clinical need for molecular assays that identify patients more likely to respond. Here, we report ultrasensitive measures circulating tumor DNA (ctDNA) and T-cell expansion can be used assess responses immune checkpoint blockade in metastatic lung cancer (N = 24). Patients with response therapy had a complete reduction ctDNA levels after initiation therapy, whereas nonresponders no significant changes or increase...
Abstract Purpose: Although immunotherapy is the mainstay of therapy for advanced non–small cell lung cancer (NSCLC), robust biomarkers clinical response are lacking. The heterogeneity responses together with limited value radiographic assessments to timely and accurately predict therapeutic effect—especially in setting stable disease—calls development molecularly informed real-time minimally invasive approaches. In addition capturing tumor regression, liquid biopsies may be informative...
<div>Abstract<p>Despite the initial successes of immunotherapy, there is an urgent clinical need for molecular assays that identify patients more likely to respond. Here, we report ultrasensitive measures circulating tumor DNA (ctDNA) and T-cell expansion can be used assess responses immune checkpoint blockade in metastatic lung cancer (<i>N</i> = 24). Patients with response therapy had a complete reduction ctDNA levels after initiation therapy, whereas nonresponders...
Although immunotherapy is the mainstay of therapy for advanced non-small cell lung cancer (NSCLC), robust biomarkers clinical response are lacking. The heterogeneity responses together with limited value radiographic assessments to timely and accurately predict therapeutic effect -especially in setting stable disease-call development molecularly-informed real-time minimally invasive predictive biomarkers. In addition capturing tumor regression, liquid biopsies may be informative evaluating...
<p>Supplementary Fig.S9 Comparison between plasma proteomic profiles across treatment timepoints and toxicity. Heatmaps showing normalized protein expression (NPX) scores for 92 proteins evaluated using Olink analyses all (A) baseline (n=19) (B) on-therapy (n=47) samples from 28 patients. Panels indicating timepoint the presence or absence of immunotherapy-related toxicity are displayed below heatmaps.</p>